Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany

Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg J-M (2009)
BREAST CARE 4(6): 389-396.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ; ;
Abstract / Bemerkung
Background: Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context. Patients and Methods: To assess the cost effectiveness of switching to exemestane vs. continued tamoxifen therapy for early-stage breast cancer, a Markov model was developed. The model population was set as postmenopausal women who are in remission from early-stage breast cancer. Upon model entry, either a continuing daily therapy with 20 mg tamoxifen or a switch to 25 mg exemestane for the next 2-3 years takes place. The model takes a German health care perspective. Results: The total incremental costs of exemestane on a lifetime basis are 4,195 Euro, resulting in an incremental cost effectiveness ratio of 17,632 Euro per additional quality-adjusted life year (QALY), or 16,857 Euro per life year gained. Incremental costs per disease-free year of survival are 12,851 Euro. Probabilistic sensitivity analyses proved the robustness of these findings. Conclusion: Compared to extended tamoxifen therapy, switching to exemestane after 2-3 years turned out to be a cost-effective strategy in adjuvant therapy for early-stage breast cancer in postmenopausal women within the German health care context.
Stichworte
Aromatase inhibitors; Cost effectiveness; Breast cancer; Early stage; Postmenopause
Erscheinungsjahr
2009
Zeitschriftentitel
BREAST CARE
Band
4
Ausgabe
6
Seite(n)
389-396
ISSN
1661-3805
eISSN
1661-3805
Page URI
https://pub.uni-bielefeld.de/record/1588884

Zitieren

Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg J-M. Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE. 2009;4(6):389-396.
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., & von der Schulenburg, J. - M. (2009). Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE, 4(6), 389-396. doi:10.1159/000255840
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., and von der Schulenburg, J. - M. (2009). Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE 4, 389-396.
Braun, S., et al., 2009. Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE, 4(6), p 389-396.
S. Braun, et al., “Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany”, BREAST CARE, vol. 4, 2009, pp. 389-396.
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., von der Schulenburg, J.-M.: Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE. 4, 389-396 (2009).
Braun, Sebastian, Mittendorf, Thomas, Menschik, Thomas, Greiner, Wolfgang, and von der Schulenburg, Johann-Matthias. “Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany”. BREAST CARE 4.6 (2009): 389-396.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 20877674
PubMed | Europe PMC

Suchen in

Google Scholar